•  

Posts Tagged: The Hospital for Sick Children (SickKids)

LAB150 adds two projects: Cystic Fibrosis and Respiratory Syncytial Virus

Toronto, ON, Feb. 27, 2019 (GLOBE NEWSWIRE) -- MaRS Innovation announced today the concurrent launch of two new LAB150 projects. These projects build on breakthroughs in disease-focused scientific research by prominent teams at The Hospital for Sick Children (SickKids) and the University of Toronto, both of which are Members of MaRS Innovation. LAB150 is a partnership between MaRS Innovation and Evotec AG with the goal of accelerating academic research towards commercial outcomes by providing funding and access to pharmaceutically validated platforms ... Read more

ScarX announces approval for trial of first clinically-promising scar reduction cream

Toronto, August 18, 2016 – Toronto-based ScarX Therapeutics (ScarX) has received approval from Health Canada to begin a Phase I clinical trial of its SCX-001 nefopam cream, a first-of-its-kind topical treatment developed to significantly reduce surgical scarring. This announcement was covered in Yahoo Finance, The Canadian Business Journal, Global News Wire, and BioSpace. Applied immediately after surgical wound closure, SCX-001 reduces the amount of scar tissue that develops during the body’s natural healing process. The 24-subject Phase I clinical trial will be conducted at ... Read more

MaRS Innovation highlighted in the ExcelleNCE newsletter

MaRS Innovation was highlighted in the Networks of Centres of Excellence (NCE) newsletter on Wednesday, June 22. The article is titled, "MaRS Innovation revolutionizes approach to commercialization, " and discusses the success of the MaRS Innovation commercialization model. The article mentions companies such as ScarX Therapeutics, a spin-off of MI and Toronto’s Hospital for Sick Children that is commercializing a topical prescription cream. It also talks about Encycle Therapeutics, a Toronto biotechnology start-up from the University of Toronto, that has developed a fast, ... Read more

Johnson & Johnson Innovation Opens JLABS @ Toronto

TORONTO (May 11, 2016) –  Johnson & Johnson Innovation LLC, today announced the opening of JLABS @ Toronto, a new 40,000-square-foot life sciences incubator, providing entrepreneurs shared lab space and offices, modular lab suites and access to scientific, industry and capital funding experts as they work to build important and successful early-stage companies. The new JLABS facility can accommodate up to 50 start-ups and opens with 22 companies that represent a range of sectors including therapeutics, medical devices and consumer health ... Read more

ScarX Therapeutics closes $2 million Series A financing

Canadian biotech company developing ground-breaking therapeutic designed to minimize dermal scarring (fibrosis)   TORONTO (February 16, 2016) — ScarX Therapeutics, a Canadian biotechnology company commercializing innovative treatments for dermal scarring (fibrosis), has closed a $2 million Series A financing. The company will complete a Phase I clinical trial of its lead candidate, SCX-001, in human volunteers, with the eventual goal of creating better functional and cosmetic patient outcomes. This announcement was covered in TechVibes, BetaKit, Biotechnology Focus, PEHub, Finsmes, and StartupHere Toronto. SCX-001 is the ... Read more

Accel-Rx and BDC Capital make second portfolio investment in ScarX Therapeutics

MaRS Innovation portfolio company completing Phase 1 human clinical trial of drug to prevent dermal scarring VANCOUVER (February 16, 2016) — Accel-Rx Health Sciences Accelerator (Accel-Rx), a Centre of Excellence for the Commercialization of Research (CECR), and its partner BDC Capital today announced their second joint investment in ScarX Therapeutics, a Canadian biotechnology company commercializing innovative treatments for dermal scarring (fibrosis). Accel-Rx and BDC Capital, and other investors including MaRS Innovation, have invested a total of $2 million in ScarX. This investment will ... Read more

Ontario advancing nine medical research projects in cancer, heart disease and sleep apnea to market

Applications for next MSc PoP granting round being accepted until February 25, 2016 TORONTO (January 26, 2016) — Nine Ontario-based medical research projects built on great science with potential for significant economic impact are advancing a step closer to market entry thanks to funding from Ontario Centres of Excellence’s Medical Sciences Proof-of-Principle (MSc PoP) program. The projects range from cancer to heart disease to sleep apnea in children. Applications for the next MSc PoP granting round are open until March 4, 2016. To ... Read more

Ontario Government, University of Toronto, and MaRS secure Johnson & Johnson Innovation, JLABS for Toronto – first JLABS Incubator outside of United States

Partners for JLABS @ Toronto include Janssen Inc., MaRS Innovation and seven of MI's 15 member institutions   TORONTO, Sept. 8, 2015 — The Ontario Government, University of Toronto, and MaRS Discovery District (MaRS) today announced a collaboration with Janssen Inc. to launch the successful Johnson & Johnson Innovation, JLABS incubator model in Toronto. This announcement has been covered in the Toronto Star, Metro News Canada, Sing Tao Daily, OurWindsor.ca, FierceBiotech, BioCentury, MedCity News, BioSpace, Biotechnology Focus, Lab Product News, ChinaNews.com, Pan European Networks, Economic ... Read more

Federal government awards the University of Toronto $114-million regenerative medicine grant

On Tuesday, July 28, 2015, the federal government announced a $114-million grant to cement the University of Toronto's position as one of the world's leading centres for the design and manufacture of cells, tissues and organs to treat degenerative disease. This announcement was covered in The Globe & Mail and Lab Products News, and by CBC.ca, CTV News and Global TV. MaRS Innovation was specifically mentioned as a commercialization partner in the Toronto Star's coverage. As the university's commercialization agent, MaRS Innovation welcomes this ... Read more

Ontario Government Invests $1 Million in Toronto’s Neuroscience Catalyst Consortium

Ministry of Research & Innovation joins founding partners University of Toronto and Janssen Inc., and new partners Evotec AG, MaRS Innovation and Ontario Centres of Excellence, to advance treatments for neurological disorders and develop early-stage biotech companies TORONTO and PHILADELPHIA (June 16, 2015)— Toronto’s neuroscience efforts to find new drugs to treat and manage brain disorders — specifically, mood disorders and Alzheimer's disease — took another step forward as the Government of Ontario’s Ministry of Research and Innovation announced a $1 million ... Read more
Page 1 of 3123